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Abstract
Background. Distinct histone modifications regulate gene
expression in certain diseases but little is known about his-
tone epigenetics in diabetic nephropathy. The current study
examined the role of histone epigenetics in development
and progression of nephropathy in db/db mice.
Methods. We studied kidney damage in 6-month-old non-
diabetic mice and type 2 diabetic db/db mice that under-
went either sham surgery or uninephrectomy at 6 weeks
of age which accelerates glomerulosclerosis in db/db mice
via glomerular hyperfiltration. Histone H3K9 and H3K23
acetylation, H3K4 and H3K9 dimethylation and H3 phos-
phorylation at serine 10 was explored by western blotting
of renal histone extracts.
Results. Uninephrectomy in C57BL/6 mice or onset of
diabetes in type 2 diabetes reduced renal H3K23 acety-
lation, H3K4 dimethylation and H3 phosphorylation at
serine 10. In contrast, H3K9 and H3K23 acetylation,
H3K4 dimethylation and H3 phosphorylation at serine
10 were significantly increased in uninephrectomized
db/db mice. The disease pattern of these mice is charac-
terized by an increased glomerular cell proliferation, se-
vere glomerulosclerosis, albuminuria and glomerular
filtration rate reduction. Treating uninephrectomized
db/db mice with a Mcp-1/Ccl2 antagonist prevented
the histopathological damage and the aforementioned
histone modification abnormalities of advanced diabetic
glomerulosclerosis.
Conclusion. We conclude that advanced diabetic nephrop-
athy is associated with increased renal H3K9 and H3K23
acetylation, H3K4 dimethylation and H3 phosphorylation
at serine 10 that enhance chromatin unfolding and gene
expression.
Keywords: chemokine; diabetic nephropathy; epigenetics; histone H3;
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Introduction
Diabetic nephropathy (DN) is a common complication of
type 1 and type 2 diabetes and has become the leading
cause worldwide of chronic and end-stage renal disease
[26]. Histopathologically, DN is characterized by progres-
sive remodelling of the glomerular structure, i.e. thicken-
ing of the glomerular basement membrane, activation of
mesangial cells that produce increasing amounts of diffuse
and nodular mesangial matrix deposits and podocyte dam-
age altogether leading to glomerulosclerosis [9]. These
structural alterations cause progressive hyperfiltration of
the remaining glomeruli and albuminuria. As glomerulo-
sclerosis become severe, glomerular filtration rate (GFR)
declines, and DN progresses to end-stage renal disease.
Numerous molecular pathways have been identified that
link the metabolic abnormalities of diabetes to glomerular
hyperfiltration and glomerular cell activation including hy-
perglycaemia and the generation of glycation end products
[21], JAK/STAT expression [4], p38 MAPK [1], local
TGF-β production [12,23], endothelial dysfunction [25],
oxidative stress [6] and activation of NF-κB-dependent in-
flammatory genes [27].
Nuclear translocation of transcription factors represents
the link between activation of outside-in signaling path-
ways and the expression of target genes involved in DN.
However, nuclear translocation of transcription factors is
required but not sufficient for gene activation. The acces-
sibility of chromatin transcription factor binding sites is
determined by the position and compaction of histones,
proteins that wind up the double-stranded DNA in nucleo-
somes. Whether the nucleosomes are packed in the chro-
matin more or less tightly is determined by the activity of a
number of enzymes that regulate the covalent modification
of distinct amino acids in histones through processes such
as acetylation, methylation and phosphorylation [3,13].
For example, histone H3 acetylation at lysines 9, 14, 18
and 23 or mono- or dimethylation at lysine activate chro-
© The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
 at U







matin for transcription factor binding while histone H3 di-
or trimethylation at lysines 9 and 27 rather silence chroma-
tin by inhibiting transcription factor accessibility [32]. An
increasing number of reports describe the association of
distinct histone modifications with carcinogenesis [31]
and autoimmunity [29], but little is known about its role
in diabetes. Patients with type 1 or/and type 2 diabetes dis-
play increased H3 acetylation at TNF-alpha and COX-2
promoters in human blood monocytes [16]. Indirect evi-
dence for a role of histone acetylation in diabetes is re-
ferred to in a study that describes trichostatin A, a
histone deacetylase inhibitor, as an agent preventing glo-
merulosclerosis in diabetic rats (Ha H et al. Nephrol Dial
Transpl 2006; 21(Suppl 2): iv33).
We hypothesized that the evolution of diabetic kidney
disease is associated with distinct histone H3 modifica-
tions. We performed Western blotting of renal histone ex-
tracts obtained from db/db mice with type 2 diabetes to
evaluate histone H3K9 and H3K23 acetylation, dimethyla-
tion of H3K4 and H3K9 and H3 phosphorylation at serine
10. Furthermore, we hypothesized that preventing the pro-
gression of kidney disease in db/db mice could potentially
revert abnormal histone modification patterns, an assump-
tion that is supported by our results.
Material and methods
Animal studies
Male 5-week-old C57BLKS db/db or C57BLKS wild-type mice were
obtained from Taconic (Ry, Denmark) and housed in filter top cages
with a 12-hour dark/light cycle and had unlimited access to food and
water throughout the study. At the age of 6 weeks, uninephrectomy (1K
mice) or sham surgery (2K mice) was performed through a 1-cm flank
incision as previously described in db/db and wild-type mice [20]. In
mice of the sham surgery groups, the kidney was left in situ. At the age
of 3 months, 1K db/db mice were divided into four groups of 12 mice
each that received subcutaneous injections three times per week as fol-
lows: (i) 5% glucose (vehicle, 10 ml/kg) from month 3–6 of age; (ii) 50
mg/kg of the anti-Ccl2 Spiegelmer mNOX-E36 (PEGylated at the 3′
end with a 40-KD-branched PEG) in vehicle from month 3–6 of age;
(iii) 50 mg/kg PoC–PEG, a non-functional control Spiegelmer with a
scrambled sequence in vehicle from month 3–6 of age; (iv) anti-Ccl2 Spie-
gelmer from month 5–6 of age. At the end of month 6, tissues were ob-
tained for histopathological evaluation 3–4 hours after the last injection.
The binding specificity, in vitro and in vivo potential of mNOX-E36 to in-
hibit murine Ccl2 (5′-GGCGACAUUGGUUGGGCAUGAGGCGA-
GGCCCUUUGAU GAACCGCGGCCA-3′) and the non-functional
control Spiegelmer (5′-UAAGGAAACUCGGUCUGAUGC GGUAGCG-
CUGUGCAGAGCU-3′) have been characterized in vitro and in vivo with
regard to their binding affinity and specificity to mCCL2 and concerning
their respective pharmacokinetics in uninephrectomized db/db mice
[14,19]. All experimental procedures had been approved by the local gov-
ernment authorities.
Assessment of diabetes and renal function
Blood glucose levels were monitored at monthly intervals (Accu check
sensor, Roche, Mannheim, Germany), and urine samples were collected
at monthly intervals for the analysis of urinary albumin (ELISA: Bethyl
Labs, Montgomery, TX, USA) and urinary creatinine levels (Jaffé reac-
tion: DiaSys Diagnostic Systems, Holzheim, Germany). GFR was deter-
mined by clearance kinetics of plasma FITC–inulin (Sigma-Aldrich,
Steinheim, Germany) 5, 10, 15, 20, 35, 60 and 90 minutes after a single
bolus injection [20]. Fluorescence was determined with 485-nm excita-
tion and read at 535-nm emission. GFR was calculated based on a two-
compartment model using a non-linear regression curve-fitting software
(GraphPad Prism, GraphPad Software Inc., San Diego, CA).
Histopathological evaluation and immunostaining
From each mouse, parts of the kidneys were fixed in 10% formalin in PBS
and embedded in paraffin. Two-micrometre sections were stained with pe-
riodic acid–Schiff reagent following the instructions of the supplier (Bio-
Optica, Milano, Italy). Glomerular sclerotic lesions were assessed using a
semiquantitative score by a blinded observer as follows: 0 = no lesion, 1 =
<25% sclerotic, 2 = 25–49% sclerotic, 3 = 50–74% sclerotic, 4 = 75–
100% sclerotic, respectively, as described [19]. Fifteen glomeruli were
analysed per section. All immunohistological studies were performed on
paraffin-embedded sections as described [19]. The following rat and rab-
bit antibodies were used as primary antibodies: rat anti-Mac-2 (glomerular
macrophages, Cederlane, Ontario, Canada, 1:50) and anti-Ki-67 (cell pro-
liferation, Dianova, Hamburg, Germany, 1:25).
Histone extraction and immunoblotting
Kidneys from mice were dissected, and histone extraction and immuno-
blotting were performed as described [28]. Briefly, kidneys were homog-
enized and processed for nucleus isolation. Nuclei were suspended in low
salt buffer (10 mM Tris, 10 mM NaCl, 10 mM EDTA, 10 μg/ml aprotinin,
10 μg/ml leupeptin and 1 mM phenyl methane sulfonyl fluoride). His-
tones were extracted in 0.25 M HCl and precipitated by adding 20% tri-
chloroacetic acid. The precipitate was washed initially with acetone with
HCl (0.25 M) followed by acetone wash. After quantification, equal
amounts of proteins (measured in micrograms) were loaded in each well
of a 14% SDS–polyacrylamide gel and transferred to an Immobilon-P
membrane (Millipore, Eschborn, Germany). Immunoblot analysis was
performed by using anti-acetylated histone H3 at lysine 23 (rabbit
1:5000), anti-phosphorylated histone H3 at serine 10 (rabbit 1:5000), di-
methylated histone H3 at lysine 4 and 9 (rabbit 1:5000), anti-histone H3
(rabbit 1:5000) and horseradish peroxidase-conjugated anti-rabbit second-
ary antibodies (all antibodies from Cell Signaling Technology, Danvers,
MA). Enhanced chemiluminescence was used for developing blots
(Amersham, Freiburg, Germany).
Statistical analysis
Data are presented as mean ± SEM. Comparison of groups was per-
formed using ANOVA and post hoc Bonferroni's correction was used
for multiple comparisons. A value of p <0.05 was considered to indi-
cate statistical significance.
Results
Early glomerulosclerosis in db/db mice is associated
with reduced histone H3K9 and H3K23 acetylation,
H3K4 dimethylation and H3 phosphorylation at serine 10
At 6 months of age, nephropathy of obese db/db mice
was characterized by mild to moderate glomerulosclerosis
but neither with a significant decline in GFR (Figure 1)
and only little albuminuria (supplementary Figure 1) as
compared to age-matched C57BL/6 mice. We questioned
whether early glomerular remodelling in db/db mice is
associated with alterations in epigenetic histone modifica-
tion patterns in kidneys of db/db mice, hence, we ex-
tracted histones from kidneys of db/db and C57BL/6
mice at 6 months of age. Western blotting of histone ex-
tracts revealed that early glomerulosclerosis of db/db
mice was associated with a decrease in H3 acetylation
at lysine 9 and 23, H3 dimethylation at lysine 4 and
H3 phosphorylation at serine 10 (Figure 2). In contrast,
H3 dimethylation at lysine 9 was not affected by type
2 diabetes (Figure 2). These abnormalities developed be-
tween 3 and 6 months of age as no such differences
could be detected at 6 or 12 weeks (supplement
Figure 2A and C). Thus, early glomerulosclerosis of
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db/db mice is specifically associated with decreased
H3K9 and H3K23 acetylation, H3K4 dimethylation and
H3 phosphorylation at serine 10.
Uninephrectomy accelerates glomerulosclerosis in db/db
mice in association with increased H3K9 and H3K23
acetylation, H3K4 dimethylation and H3 phosphorylation
at serine 10
The metabolic changes of type 2 diabetes and glomerular
hyperfiltration both contribute to the progression of early
to late DN. Consistent with our previous reports [18,19],
uninephrectomy performed at 6 weeks of age enhanced
the progression of kidney disease as documented by a sig-
nificant decline in GFR and increased presence of severe
diffuse glomerulosclerosis at 6 months (Figure 1A and B).
The progression of glomerulosclerosis was associated with
increased numbers of glomerular leukocytes and Ki-67-
positive proliferating glomerular cells as compared to
age-matched 2K db/db or C57BL/6 mice of the same
age (Figure 1C and D). We questioned whether progressive
glomerulosclerosis in 1K db/db mice is associated with
further alterations in the aforementioned epigenetic histone
modification pattern observed in kidneys of 2K db/db
mice. Western blotting revealed that advanced glomerulo-
sclerosis in 1K db/db mice was associated with an increase
of H3K9 and H3K23 acetylation, H3K4 dimethylation and
H3 phosphorylation at serine 10 as compared to age-
matched 2K db/db mice (Figure 2).
The increase of H3K23 acetylation and phosphorylation
at serine 10 was more pronounced in 1K db/db mice as
compared to age-matched C57BL/6 mice whereas H3K9
acetylation and H3K4 dimethylation were not significantly
different (Figure 2).
Uninephrectomy has opposite effects on histone
modifications in non-diabetic mice
These aforementioned observations were specific for the
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Fig. 1. Kidney disease in db/db mice. (A) Glomerular filtration rate (GFR) was measured by FITC–inulin clearance kinetics in 6-month-old C57BL/6
wild-type mice (B6), sham-operated db/db mice (db 2K) and in uninephrectomized db/db mice (db 1K). Data represent means ± SEM from five to 10
mice. **P < 0.01. Renal sections from mice of the different groups were stained with periodic acid–Schiff (PAS) and scored for the extent of
glomerulosclerosis as described in methods. The graph illustrates the mean percentage of each score ± SEM from all mice in each group (n = 7–
10). Note that uninephrectomy was associated with a shift towards higher scores of glomerulosclerosis. (B) Images show representative PAS-
stained glomeruli as indicated (original magnification ×400). (C and D) Mac2 macrophages (C) and Ki67-positive proliferating cells (D) were
identified by immunostaining on renal section from 6-month-old mice of all groups (n = 7–10). Data represent means ± SEM from 15 cortical
glomerular cross-sections. *P < 0.05 versus B6 2K, #P < 0.05 versus db 2K.
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and type 2 diabetes since uninephrectomy in non-diabetic
B6 mice rather reduced renal H3K23 acetylation, H3K4 di-
methylation and phosphorylation at serine 10 and had no ef-
fect on modifications at H3K9 (Figure 2). Thus, advanced
diabetic kidney disease in db/db mice is specifically associ-
ated with increased H3K9 and H3K23 acetylation, H3K4
dimethylation and H3 phosphorylation at serine 10 in
kidneys.
Preventing the progression of glomerulosclerosis by Ccl2
blockade reverses H3K9 and H3K23 acetylation, H3K4
dimethylation and H3 phosphorylation at serine 10
As distinct renal histone modifications correlate with the
progression of DN, preventing disease progression with
suitable interventions should revert this histone modifica-
tion pattern. We have previously shown that Mcp-1/Ccl2
blockade with a suitable inhibitor (Spiegelmer mNOX-
E36) from month 4–6 prevents diffuse glomerulosclerosis
and improves GFR in 1K db/db mice by blocking glomer-
ular recruitment of chemokine receptor Ccr2-positive
macrophages [19]. Here, we initiated Ccl2 blockade in
1K db/db mice either at month 3 or 5 of age and assessed
renal function, renal histopathology and histone epige-
netics at 6 months of age. Independent of the treatment du-
ration, Ccl2 blockade in 1K db/db mice improved GFR to
the same degree (Figure 3A) and reduced albuminuria and
glomerulosclerosis consistently (Figures 3B, C, D) with-
out affecting blood glucose levels or body weight (supple-
ment Figure S3). Immunoblotting of renal nuclear extracts
revealed that Ccl2 blockade significantly reduced the en-
hanced H3K9 and H3K23 acetylation, H3K4 dimethyla-
tion and H3 phosphorylation at serine 10 for the
treatment period months 3–6 (Figure 4). For the shorter
treatment period (months 5–6), only H3K23 was signifi-
cantly reduced whereas other modification sites displayed
only a trend towards a reduced modification. In addition,
the longer treatment also led to a reduction of H3K9 di-
methylation although this site was unchanged in the com-
parison of 2K db/db mice vs. wild-type and 1K db/db,
respectively. Could that observation simply relate to Spie-
gelmer exposure? Treating age-matched 2K db/db mice
with the same Spiegelmer for 3 months did not affect his-
tone H3 modifications which excluded this possibility
(supplement Figure S2B and C). Thus, preventing renal
disease progression reverts the histone H3 modifications
that are associated with uninephrectomy-accelerated glo-
merulosclerosis in db/db mice with type 2 diabetes.
Discussion
Our data confirmed not only our hypothesis that the evo-
lution of DN is associated with distinct histone H3 modi-
fications in db/db mice but also that these modifications
no longer persist when diffuse glomerulosclerosis is pre-
vented by Ccl2 blockade. Thus, histone H3K9 and
H3K23 acetylation, H3K4 dimethylation and phosphoryla-
tion at serine 10 correlate with the severity of advanced
glomerulosclerosis in type 2 diabetes.
Covalent modifications of histone residues determine
chromatin structure dynamics and transcription factor ac-
cessibility, i.e. epigenetic control of chromatin replication
and gene transcription [5,13]. Not much is known about
histone epigenetics in diabetes but a recent study sug-
gested that high glucose levels activate the histone acety-
lases CBP and p/CAF to increase H3 acetylation which in
turn leads to an elevated transcription of inflammatory
genes in cultured monocytes [16]. Our results demonstrate
that advanced diabetic glomerulosclerosis is associated
with increased renal histone H3 acetylation at H3K9 and
H3K23. We found histone H3 acetylation only increased in
1K db/db mice in which early uninephrectomy enhanced
the progression to diffuse glomerulosclerosis. As unine-
phrectomy itself rather decreased histone acetylation, the
combination of type 2 diabetes and glomerular hyperfiltra-
tion seems to specifically foster histone H3K9 and H3K23
acetylation. Both of these modifications have been de-
scribed to activate chromatin and enhance gene transcrip-
tion [3,13]. In fact, gene array analyses of renal biopsies
from patients with advanced diabetic nephropathy demon-
strated the increased expression of a large number of dif-
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Fig. 2. Effect of uninephrectomy and diabetes on histone modifications in
kidneys. H3 acetylation (Lys 23 and 9), methylation (Lys 4 and 9) and
phosphorylation (Ser 10) was determined by Western blot in total kidney
histone isolates from sham-operated (2K) and uninephrectomized (1K),
wild-type (B6) as well as db/db mice at the age of 6 months. The
blots shown are representative of three different blots from histone
isolates of different mice of each group. For quantitative analysis, each
band of each isolate was normalized to the respective total histone H3
content (lowest blot). The values in the histograms represent means ±
SEM from three separate blots. *P < 0.05 versus 2K WT and †P <
0.05 versus 2K db/db.
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ferent gene families [27]. Furthermore, we observed in-
creased cell proliferation in the glomerular and tubulointer-
stitial compartment of 1K db/db mice which is consistent
with the concept that histone H3K9 and H3K23 acetyla-
tion also foster gene replication and transcription in diabet-
ic kidney disease. Histone H3K4 dimethylation has a
similar permissive effect and enhances NF-κB-dependent
gene expression of inflammatory genes in macrophages of
diabetic mice [15]. By contrast, H3K9 dimethylation re-
presses gene transcription [13]. A recent study reported in-
creased H3K9 dimethylation in lymphocytes from patients
with type 1 diabetes but also reported considerable cell type
specificity in histone methylation [17,18]. This may explain
why we could not observe any effect of either diabetes or
uninephrectomy on renal H3K9 dimethylation. By contrast,
we observed significantly less H3K4 dimethylation in
kidneys of diabetic mice as compared to non-diabetic mice.
However, uninephrectomy-induced progressive glomerulo-
sclerosis was associated with increased H3K4 dimethyla-
tion consistent with the respective H3K9 and H3K23
acetylation patterns. H3K4 methylation is associated with
activation of vascular smooth muscle cells under diabetic
conditions and contributes to metabolic memory and sus-
tained pro-inflammatory phenotype [24,30]. This may also
play a role in diabetic glomerulosclerosis because glomeru-
lar mesangial cells share many structural and functional
characteristics with vascular smooth muscle cells [26] and
significantly contribute to the remodelling process of the
glomerular matrix [23]. Histone H3 phosphorylation of
Ser-10 is another marker of chromatin relaxation and gene
expression [3,22], but its role in diabetes has not yet been
explored. Our data generate first evidence that three distinct
H3 modifications, all known to promote nucleosome un-
winding and gene expression, are consistently associated
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Fig. 3. Ccl2 blockade improves kidney disease in db/db mice. Uninephrectomized db/db mice were treated either with vehicle or anti-Ccl2 Spiegelmer
from months 3–6 or Spiegelmer from months 5–6, respectively. (A) The glomerular filtration rate (GFR) was measured by FITC–inulin clearance
kinetics at 6 months of age. Data represent means ± SEM from 10 mice. *P < 0.05 versus vehicle group. (B) Proteinuria was assessed by
calculating the ratio of urinary albumin and creatinine in spot urine samples taken at 6 months of age. Data represent means ± SEM from 10 mice.
**P < 0.01 versus vehicle group. (C) Glomerular macrophage numbers were assessed by counting Mac2-cells in 15 glomeruli of renal sections. (D)
Renal sections from mice of all groups were stained with PAS and scored for the extent of glomerulosclerosis. The graph illustrates the mean percentage
of each score ± SEM from all mice in each group (n = 10). *P < 0.05 versus vehicle group.
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with glomerular cell proliferation during the progression to
advanced diabetic glomerulosclerosis in db/db mice.
As a second finding, Ccl2 blockade reverted these his-
tone modifications together with preventing progression
of DN. Ccl2 promotes (diabetic) glomerulosclerosis by me-
diating the recruitment and intrarenal activation of macro-
phages and by direct activation of glomerular mesangial
cells [2,11]. Vice versa, loss-of-function mutations in the
Ccl2 gene prevent macrophage recruitment, inflammation
and glomerulosclerosis inmousemodels of type 1 and 2 dia-
betes [7,8]. The present study extends our previously pub-
lished data [19] by showing that a Ccl2 antagonist started as
late as at 5 months of age is sufficient to prevent diffuse glo-
merulosclerosis in 6-month-old 1K db/db mice. Remark-
ably, Ccl2 blockade also reduced histone H3K9 and
H3K23 acetylation, H3K4 dimethylation and H3 phospho-
rylation at serine 10, suggesting a role for Ccl2 in the regu-
lation of histone epigenetics. However, the shorter (months
5–6) compared to the longer (months 3–6) treatment period
did not lead to a statistically significant reduction of the
histone modification pattern, although both treatment
periods showed equally strong effects on the GFR, the
urinary albumin/creatinine ratio and the extent of glo-
merulosclerosis. Yet it remains unclear whether these
histone modifications represent only markers of disease
progression or whether they directly promote the tran-
scription of pathogenic genes. Evidence for the latter
concept comes from a preliminary report describing ben-
eficial effects of the histone deacetylation inhibitor tri-
chostatin A on glomerulosclerosis in diabetic rats [10].
In summary, the progression of DN in db/db mice with
type 2 diabetes is associated with global renal histone
H3K9 and H3K23 acetylation, H3K4 dimethylation and
phosphorylation at serine 10. Future studies will have to
define how single modifications regulate the expression
of pathogenic genes in distinct glomerular cell types and
whether modifying histone epigenetics, e.g. with specific
enzyme inhibitors, may represent a novel strategy to pre-
vent DN.
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Abstract
Background. Cardiovascular disease is one of the major
causes of mortality and morbidity in patients with end-stage
renal disease (ESRD). It is characterized by multiple left
ventricular abnormalities, referred to as ‘uraemic cardiomy-
opathy’. The aim of the study was to investigate uraemic
cardiac disease in a mouse model of chronic renal failure
induced by subtotal nephrectomy and to evaluate the impact
of the tyrosine kinase inhibitor imatinib and its antifibrotic
as well as functional properties on the extent of the disease.
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